List of Drugs for an Urgent Public Health Need
The List of Drugs for an Urgent Public Health Need (the List) contains the following drug-related details: the brand name, the medicinal ingredient(s), the route of administration, the strength, the dosage form and the identifying code or number, if any, assigned in the country in which the drug was authorized for sale.
The List also contains other information obtained through the public health official notification, including: the foreign regulatory authority which authorized the drug, the foreign country from which the drug can be imported, the Canadian jurisdiction notifying for the drug (i.e., the Canadian jurisdiction in which the drug is allowed to be sold), the urgent public health need for the drug, the intended use or purpose of the drug (i.e., the purpose for which the drug must be used in the Canadian jurisdiction) and the date of notification by a public health official.
A public health official notification allows a listed drug to be imported into Canada and sold in the notifying jurisdiction for a period of 1 year. If a notification has not been renewed by a public health official within one year of the initial notification, the drug will no longer be eligible for importation and sale. Drugs may also be removed from the List at any time at the Minister's discretion.
A drug is only eligible for importation and sale if all columns on the List are populated, including columns located under the "For Information Purposes" subheading.
| Brand name Medicinal Ingredient(s) | Dosage form Strength Route of administration |
Foreign identifying code or number | For Information Purposes | ||
|---|---|---|---|---|---|
| Foreign regulatory authority/ Foreign country | Canadian jurisdiction notifying for the drug/Date of notification by a public health official | Urgent public health need - Applicable Foreign Authorised Indication (Intended use or purpose of the drug) | |||
| Priftin Rifapentine |
Tablet 150mg Oral |
0088-2100-24 | FDA/USAFootnote 1 Important foreign identified risk information-see footnote below |
First Nations and Inuit Health Branch/ August 15, 2023 |
Tuberculosis crisis – For the treatment of latent tuberculosis infection (LTBI) caused by Mycobacterium tuberculosis in combination with isoniazid in patients at high risk of progression to TB disease. |
| Priftin Rifapentine |
Tablet 150 mg Oral |
0088-2102-24 | FDA/USAFootnote 1 Important foreign identified risk information-see footnote below |
Public Health Agency of Canada - for use in all jurisdictions/ February 20, 2024 |
Tuberculosis crisis – For the treatment of latent tuberculosis infection (LTBI) caused by Mycobacterium tuberculosis in combination with isoniazid in patients at high risk of progression to TB disease. |
Footnotes
- Footnote 1
-
Foreign Identified Risk: Rifapentine has been identified by the US FDA as one of the drugs that contains nitrosamine impurities. For more information, please visit the US FDA website:
https://www.fda.gov/drugs/drug-safety-and-availability/fda-works-mitigate-shortages-rifampin-and-rifapentine-after-manufacturers-find-nitrosamine
Related Information:
Page details
- Date modified: